Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM, Berends-van der Meer DM, Löwik MJ, Hamming IL, van Esch EM, Hellebrekers BW, van Beurden M, Schreuder HW, Kagie MJ, Trimbos JB, Fathers LM, Daemen T, Hollema H, Valentijn AR, Oostendorp J, Oude Elberink JH, Fleuren GJ, Bosse T, Kenter GG, Stijnen T, Nijman HW, Melief CJ, van der Burg SH. van Poelgeest MI, et al. Among authors: hollema h. Clin Cancer Res. 2016 May 15;22(10):2342-50. doi: 10.1158/1078-0432.CCR-15-2594. Epub 2016 Jan 26. Clin Cancer Res. 2016. PMID: 26813357 Clinical Trial.
Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery.
Nijhuis ER, van der Zee AG, in 't Hout BA, Boomgaard JJ, de Hullu JA, Pras E, Hollema H, Aalders JG, Nijman HW, Willemse PH, Mourits MJ. Nijhuis ER, et al. Among authors: hollema h. Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):699-705. doi: 10.1016/j.ijrobp.2006.05.039. Epub 2006 Aug 14. Int J Radiat Oncol Biol Phys. 2006. PMID: 16904839
An overview of innovative techniques to improve cervical cancer screening.
Nijhuis ER, Reesink-Peters N, Wisman GB, Nijman HW, van Zanden J, Volders H, Hollema H, Suurmeijer AJ, Schuuring E, van der Zee AG. Nijhuis ER, et al. Among authors: hollema h. Cell Oncol. 2006;28(5-6):233-46. doi: 10.1155/2006/273547. Cell Oncol. 2006. PMID: 17167177 Free PMC article. Review.
P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.
Lambeck A, Leffers N, Hoogeboom BN, Sluiter W, Hamming I, Klip H, ten Hoor K, Esajas M, van Oven M, Drijfhout JW, Platteel I, Offringa R, Hollema H, Melief K, van der Burg S, van der Zee A, Daemen T, Nijman H. Lambeck A, et al. Among authors: hollema h. Int J Cancer. 2007 Aug 1;121(3):606-14. doi: 10.1002/ijc.22710. Int J Cancer. 2007. PMID: 17415711 Free article.
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.
Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW. Leffers N, et al. Among authors: hollema h. Cancer Immunol Immunother. 2009 Mar;58(3):449-59. doi: 10.1007/s00262-008-0583-5. Epub 2008 Sep 13. Cancer Immunol Immunother. 2009. PMID: 18791714 Free PMC article.
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
Duiker EW, de Vries EG, Mahalingam D, Meersma GJ, Boersma-van Ek W, Hollema H, Lub-de Hooge MN, van Dam GM, Cool RH, Quax WJ, Samali A, van der Zee AG, de Jong S. Duiker EW, et al. Among authors: hollema h. Clin Cancer Res. 2009 Mar 15;15(6):2048-57. doi: 10.1158/1078-0432.CCR-08-1535. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276284 Free article.
277 results